

정신분열병에서 Quetiapine의 임상적 효과와 안전성

김 찬 형^{1,2} · 김 영 기¹연세대학교 의과대학 정신과학교실,¹ 의학행동과학연구소²

ABSTRACT

Efficacy, Safety, and Tolerability of Quetiapine in Patients with Schizophrenia

Chan-Hyung Kim, MD, PhD^{1,2} and Young-Kee Kim, MD¹¹Department of Psychiatry and ²Institute of Behavioral Science in Medicine,
Yonsei University College of Medicine, Seoul, Korea

Atypical antipsychotics have an improved tolerability profile, and are less likely to cause debilitating extrapyramidal symptoms (EPS) than are the conventional antipsychotics. Quetiapine, the fourth atypical antipsychotic, was marketed in Korea as well as in the United States and is also available in over 70 countries worldwide. Quetiapine has been shown to be effective and well tolerated in patients particularly vulnerable to EPS related to conventional antipsychotics. In this article, we review the clinical trials examining the efficacy, safety, and tolerability of quetiapine in treating patients with schizophrenia. (Korean J Psychopharmacol 2004;15(2):135-143)

KEY WORDS : Atypical antipsychotics · Quetiapine · Schizophrenia.

서	론	가
1	chlorpro-	(atypical antipsychotics)'
mazine	.	. quetiapine
,	,	1997 9 FDA
,	,	2000
가	.	quetia-
.	pine	,
2003 5	,	quetiapine

교신저자 : , 135 - 720 146 - 92

: (02) 3497 - 3340 · : (02) 3462 - 4304

E - mail : spr88@yumc.yonsei.ac.kr

임상 연구들

quetiapine

Quetiapine

6 가 .¹⁻³⁾ quetiapine 가 .⁷⁾ post hoc reanalysis BPRS 30% quetiapine haloperidol (p=.042).¹¹⁾ . Borison ¹⁾ quetiapine 가 (BPRS 40% quetiapine 150 mg, 750 mg 가 . Avantis Miller ²⁾ quetiapine 300 mg, 600 mg (p<.0083).²⁾ pine 가 haloperidol(12 mg) (250 mg) (750 mg) ³⁾ quetiapine (250 mg) , quetiapine (750 mg) 가 .³⁾ quetiapine (6~24)가 . Peuskens Link ⁴⁾ 6 quetiapine 가 (750 mg) chlorpromazine(750 mg) . King ⁵⁾ 6 quetiapine CGI - S(CGI - Severity of Illness) (225 mg, 150 mg, ^{2,3)} 25 mg). Copolov ⁶⁾ 6 quetiapine quetiapine haloperidol CGI 455 mg haloperidol 8 mg 가 ,⁶⁾ CGI - S . 8 quetiapine 600 mg haloperidol quetiapine 7,8) haloperidol quetiapine . Velligan 24 quetiapine 300 mg haloperidol 9) quetiapine 455 mg quetiapine 600 mg haloperidol PANSS 가 ,⁶⁾ (quetiapine : - 18.7 ± 1.63, haloperidol - 22.1 ± 1.63). quetiapine (600 mg) haloperidol (20 mg) PANSS 4 (- 9.05 - 5.82 ; p=.061) 12 (- 11.50 - 8.87 ; p=.234) , .⁷⁾ 가 4 12 PANSS 20% , haloperidol quetiapine

임상적 치료효과

1. 전반적 증상

quetiapine , quetiapine BPRS .¹⁻³⁾ 450 mg quetiapine 50 mg BPRS ⁵⁾ 600 mg quetiapine pine 20 mg haloperidol BPRS 가 (600 mg quetiapine halo-

quetiapine 가
haloperidol 가
, quetiapine 400 mg
가
가 가
가 가

2. 양성 증상
, BPRS
가
quetiapine
, 2,3)
(250 mg)
. 1) BPRS
quetiapine haloperidol
. 2)
(750 mg)
. 17)
quetiapine 가 가 가
가 가 Sax
quetiapine
. 2
10
. quetiapine
, 2
가
. quetiapine
. 6
quetiapine haloperidol
, 19) 6
quetiapine
. quetiapine
. 3)
. quetiapine
/ chlorpromazine, haloperidol,
risperidone, olanzapine 가
. 20)
1 가 quetiapine
1
. 24
. 58
. haloperidol(12 mg) quetiapine (300
mg 600 mg) . 600 mg
quetiapine haloperidol

3. 음성 증상
, 300 mg
(p<.05). 2) halo-
peridol quetiapine
. SANS
가 (250 mg)
(750 mg)
. 3)
. quetiapine
/ chlorpromazine, haloperidol,
risperidone, olanzapine 가
. 20)
1 가 quetiapine
1
. 24
. 58
. haloperidol(12 mg) quetiapine (300
mg 600 mg) . 600 mg
quetiapine haloperidol

4. 인지
, , , ,

Quetiapine

391 ± 214 mg BPRS 가 , quetiapine
 benztro- BPRS 가 , quetiapine
 pine quetiapine (600 mg)가 haloper-
 idol quetiapine (300 mg)
 가
 quetiapine , quetiapine
 , 40 가
 4 18-22) quetiapine
 (N=20) quetiapine 가
 (N=20) 가 9) 6
 quetiapine 319 ± 143 mg 5. 정 등
 chlorpro- 60%
 mzaine 348 ± 348 mg
 (10%) (30~50%)
 23,24) 가
 24)
 60%가 benztropine qu-
 etiapine benztropine
 . quetiapine
 clozapine, risperidone, olanza-
 pine, quetiapine, ziprasidone
 (initiation), benztropine 가 가
 6 que- zapine 가 clo-
 tiapine , quetiapine 가
 21) quetiapine
 (intrusion) 가 , 25)
 (interruption)
 quetiapine quetiapine 가 Lee Meltzer
 26) quetia-
 pine haloperidol BPRS Factor (quetia-
) Kay (PA-
 NSS : , , , ,
) quetiapine
 19 quetiapine 6 가 haloperidol
 22) quetiapine 가

haloperidol (250 mg) (750 mg) , quetiapine 150 mg (250 mg) (750 mg) , BPRS Factor BPRS

18%), (quetiapine 18% 11%), (quetiapine 10% 4%) ,

가 .²⁷⁾ quetiapine , 가

.²⁷⁾ quetiapine

quetiapine(600 mg) haloperidol(20 mg) Kay Depression Factor 가 , quetiapine haloperidol , quetiapine

6. 공격성

가 .²⁵⁾ quetiapine , /haloperidol (,²⁷⁾ BPRS) 가 . quetiapine 가 , haloperidol 가

안전성과 내약성

가 (,³⁰⁾ 3 10%) (quetiapine 19%

1. 주체외로 증후군

quetiapine quetiapine 가 .²⁷⁾ quetiapine 가 (12.6% : 8.6%), . quetiapine haloperidol .²⁾ quetiapine , olanzapine, ziprasidone 가 ,²⁹⁾ quetiapine clozapine 가

2. 프로락틴과 성기능

가 . quetiapine clozapine 가가 가 .³⁾ quetiapine ,³⁰⁾ 3 6 가 .

FDA black box 가 (). ziprasidone
 가 QTc

QTc 가
 435 millisecond

5. 기타부작용

1) 수정제 혼탁

가
 (thioridazine, chlorpromazine)⁴⁰⁾
 가,
⁴¹⁾

6~12
 가
⁴²⁾
 quetiapine
 quetiapine
 4

1997 9 2002 1
 quetiapine 30
 (AstraZeneca Pharmaceutical).

quetiapine
 (10 1
). quetiapine
 가 , 가

quetiapine
 6

2) 간효소

가 transminase
 aspartate transaminase[AST])가
 quetiapine
²⁷⁾ 3

가 가 quetiapine
 6% 3 1% ⁴³⁾
 가 3
²⁷⁾

요 약

가 가
 가
 quetiapine , ,

quetiapine BPRS
 BPRS , SANS , PANSS ,
 CGI

quetiapine
 , haloperidol chlorpromazine
 가
 quetiapine 1

quetiapine , , ,
 가

quetiapine
 250~750 mg quetiapine

가
 가
 quetiapine
 , quetiapine QTc

, quetiapine
 가

중심 단어 : Quetiapine

참고문헌

1) Borison RL, Arvanitis LA, Miller BG, and the U.S. SEROQUEL Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. *J Clin Psychopharmacol* 1996;16:158-169.
 2) Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group.

Quetiapine

- Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. *Biol Psychiatry* 1997;42:233-246.
- 3) Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG, and the Seroquel Study Group. *Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry* 1997;54:549-557.
 - 4) Peuskens J, Link CG. *A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand* 1997;96:265-273.
 - 5) King DJ, Link CG, Kowalczyk B. *A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl)* 1998;137:139-146.
 - 6) Copolov DL, Link CG, Kowalczyk B. *A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med* 2000;30:95-105.
 - 7) Emsley RA, Raniwalla J, Bailey PJ, Jones AM, on behalf of the PRIZE Study Group. *A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol* 2000;15:121-131.
 - 8) Goldstein JM, Buckley P, Emsley R. *Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia. Presented at the 4th annual meeting of the College of Psychiatric and Neurologic pharmacists; March 25-28, 2001; San Antonio, Tex.*
 - 9) Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. *Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes. Presented at the 40th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii.*
 - 10) 이홍식 · 강대엽 · 송동호 · 김영신 · 전덕인 · 김세주 등. *Quetiapine의 정신분열병에 대한 효능 및 안전성에 관한 개방 연구. 대한정신약물학회지* 2004;15(1):51-57.
 - 11) Nasrallah HA, Barker N, Emsley R. *Patterns of clinical response in patients with schizophrenia treated with quetiapine or haloperidol after a suboptimal response to a fluphenazine trial. Presented at the 40th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii.*
 - 12) Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. *Neuropsychological deficit in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry* 1994;51:124-131.
 - 13) Green MF. *What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry* 1996;153:321-330.
 - 14) Velligan DI, Mahurin RK, Diamond PL, Hazletou BC, Eckert SL, Miller AL. *The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res* 1997;25:21-31.
 - 15) Heaton R, Crowley T. *Effects of psychiatric disorders and their somatic treatments on neuropsychological results. In: Filskov S, Bell TJ, eds. Handbook of Clinical Neuropsychology. New York, NY: John Wiley & Sons;1981.p.481-525.*
 - 16) Spohn HE, Strauss ME. *Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol* 1989;98:367-380.
 - 17) Meltzer HY, McGurk SR. *The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull* 1999;25:233-255.
 - 18) Sax KW, Strakowski SM, Keck PE Jr. *Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res* 1998;33:151-155.
 - 19) Purdon SE, Hellewell JSE. *The effect of quetiapine in improving cognitive impairment in schizophrenia. Presented at the 8th International Congress on Schizophrenia Research; 28-May 2, 2001; Whistler, British Columbia, Canada.*
 - 20) Velligan DI, Newcomer J, Pults J, Csernansky J, Hoff AL, Mahurin R, et al. *Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res* 2002;53:239-248.
 - 21) Mueller J, Velligan D, DiCocco M. *Quetiapine improves verbal memory in patients with schizophrenia Presented at the 42nd annual meeting of the New Clinical Drug Evaluation Unit; June 10-13 2002; Boca Raton, Fla.*
 - 22) Meltzer HY, Lee MA. *Quetiapine improves cognitive function in schizophrenia. Presented at the 8th International Congress on Schizophrenia Research; April 28-May 2, 2001; Whistler, British Columbia, Canada.*
 - 23) Siris SG. *Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry* 2000;157:1379-1389.
 - 24) Siris SG. *Suicide and schizophrenia. J Psychopharmacol* 2001;15:127-135.
 - 25) Keck PE Jr, Strakowski SM, McElroy SL. *The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry* 2000;61(suppl 3):4-9.
 - 26) Lee M, Meltzer H. *Quetiapine is significantly superior to haloperidol and placebo in improving mood in patients with schizophrenia. Presented at the 7th World Congress of Biological Psychiatry; July 1-6, 2001; Berlin, Germany.*
 - 27) Goldstein J. *Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today* 1999;35:193-210.
 - 28) Emsley RA, Buckley P, Joes AM, Greenwood MR. *Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol. Presented at the 40th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii.*
 - 29) Tandon R, Jibson MD. *Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry* 2002;14(2):123-129.
 - 30) Hamner MB, Arvanitis LA, Miller BG, Link CG, Houg WW. *Plasma prolactin in schizophrenia subjects treated with seroquel. Psychopharmacol Bull* 1996;32(1):107-110.
 - 31) Sussman N. *Review of atypical antipsychotics and weight gain. J Clin psychiatry* 2001;62(suppl 23):5-12.
 - 32) Brecher M, Rak IW, Melvin K. *The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin pract* 2000;4:287-291.
 - 33) Jones A, Rak I, Ranjwala J. *Weight changes in patients treated with quetiapine. Presented at the 153rd annual meeting of the American Psychiatric Association; May 13-18, 2000; Chicago, Ill.*
 - 34) Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. *Diabetes mellitus in schizophrenic patients. Compr Psychiatry* 1996;37:68-73.
 - 35) Nasrallah HA, Mulvihill T. *Iatrogenic disorders associated with conventional vs atypical antipsychotics. Ann Clin Psychiatry* 2001;13:215-227.
 - 36) Henderson DC. *Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs* 2002;16:77-89.
 - 37) Newcomer JW, Jaupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. *Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry* 2002;59:337-345.
 - 38) Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. *QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet* 2000;355:1048-1052.
 - 39) Glassman AH, Bigger JT Jr. *Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry* 2001;158:1774-1782.

- 40) Pfizer, Inc. *Food and Drug Administration psychopharmacological Drugs Advisory Committee. Brief document for Zeldox capsules (ziprasidone HCl). July 19, 2000. Available at: <http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf>. Accessed Sept 30, 2002.*
- 41) Isaac NE, Walker AM, Jick H. *Exposure to phenothiazine drugs and risk of cataract. Arch Ophthalmol 1991;109:256-260.*
- 42) Johnson GJ. *Limitations of epidemiology in understanding pathogenesis of cataracts. Lancet 1998;351:925-926.*
- 43) Seroquel [prescribing information]. *Wilmington, Del: Astra-Zeneca Pharmaceuticals, LP; Revised Jan:2001.*